Solebury Trout Talks: Interview with Bob Geho, Diasome - Part of the NameTag Series



Mr. Geho has twenty-five years of experience in the field of diabetes drug development and is a recognized leader in the industry’s effort to develop novel insulin therapies for people with Type 1 and Type 2 diabetes. As a patient-entrepreneur, he has been a dedicated team member and leader in the execution of more than twenty different human clinical studies designed to test various forms of both injected and oral insulins for diabetes, including the first ever Phase 2b study of oral liver targeted insulin and the first ever Phase 2b study of injected liver targeted mealtime insulin.

In his role at Diasome, he is responsible for aligning technology, clinical, and business teams in Diasome’s work to achieve the first approved liver targeted insulin therapy. Mr. Geho received his undergraduate degree from both The Cleveland Institute of Music and Case Western Reserve University and his MBA from The Weatherhead School of Management at CWRU.